Presentations Demonstrate the Power of Integrated Analysis to Discover Distinct Characteristics of the Tumor Microenvironment Leading to Positive Clinical Outcomes

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene announced today that it will participate in the 81st Annual Meeting of the Japanese Cancer Association. The event, to be held at Pacific Convention Plaza Yokohama from September 29 � October 1, will bring together leading oncologists and basic and clinical researchers in academia or industry to discuss cutting-edge findings in cancer research and recent progress in cancer, such as genomic medicine and immune therapy. BostonGene will also exhibit in Hall B, booth 87.

BostonGene will showcase how its innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient�s immune system and the effectiveness of all available approved and investigational treatments can advance how physicians treat their patients and dramatically improve clinical outcomes.

"I look forward to participating at the Annual Meeting of the Japanese Cancer Association and to presenting the clinical utility of the BostonGene Tumor Portrait^TM Tests," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "We firmly believe BostonGene's deep molecular and immune profiling, computational power, and analytics will positively impact the standard of care for cancer patients worldwide."

Details about the abstracts selected for presentation can be found below:

Abstract Number: E-1044

Title: Analytical Validation of the BostonGene Tumor Portrait Assay

Date and Time: Thursday, September 29 at 3:15 PM JST

Location: Room 7

English Oral Session Title: E7-2 Elucidating the significance of mutations through informatics and novel technologies

With the increasing use of molecular profiling to guide personalized decision-making, the analytical capabilities of next-generation sequencing (NGS) assays are critical. This presentation describes the analytical performance of the BostonGene Tumor Portrait^TM Test, which integrates whole-exome sequencing (WES) and RNA sequencing (RNA-seq).

Abstract Number: E-2073

Title: Combinatory Technology for Single Sample Gene Expression Projection onto a Cohort Sequenced with a Different Technology

Date and Time: Friday, September 30 at 1:00 PM JST

Location: Room 13

English Oral Session Title: E14-7 Gastric cancer (1)

This presentation highlights the importance of BostonGene Batch Correction technique that enables the analysis of single tumor gene expressions by comparison with datasets collected from cohorts of patients with a similar diagnosis to support personalized treatment decisions.

Abstract Number: E-3075

Title: Urothelial carcinoma (UC) subtypes defined by genomic and tumor microenvironment (TME) features predict therapy response properties for precision oncology

Date and Time: Saturday, October 1 at 1:30 PM JST

Location: Room 10

English Oral Session Title: E14-10 Basic and clinical research for urologic cancer (1)

This presentation demonstrates the ability of BostonGene�s novel transcriptome-based classification platform to identify tumor microenvironment (TME) subtypes for a specific cancer type, urothelial carcinoma, that are predictive of response to immunotherapy.

Abstract Number: P-3081

Title: Astraea: A biomarker database integrating genomic, transcriptomic, and TME properties for precision oncology

Date and Time: Saturday, October 1 at 5:15 PM

Location: Room P

Poster Session Title: P25-1 Towards Understandings of Cancer Biology from Viewpoints of Mathematical Modelings and Computational Biology

This presentation underscores the application of BostonGene�s cutting-edge analytical tools to improve treatment for cancer patients by identifying biomarkers for diverse therapies and ultimately helping guide decision-making for personalized medicine.

Click here to learn more and to register for the 81st Annual Meeting of the Japanese Cancer Association

About BostonGene Corporation

BostonGene�s mission is to power healthcare�s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait^TM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait^TM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

BostonGene
Erin O�Reilly

+1-781-366-7049

[email protected]